5 Interactions found for:
Drug Interactions
No drug interactions were found for selected drugs: prednisone, Vitamin B12.
This does not necessarily mean no interactions exist. Always consult your healthcare provider.
Drug and Food Interactions
Moderate
Prednisone
+ Food
The following applies to the ingredients: Prednisone
Using predniSONE together with alcohol or grapefruit may increase the risk of side effects of predniSONE. You may want to limit your consumption of grapefruit, grapefruit juice, and/or alcohol during treatment with predniSONE. Talk to your doctor if you have any questions or concerns. You should seek immediate medical attention if you experience any unusual bleeding or bruising, or have other signs and symptoms of bleeding such as dizziness; lightheadedness; red or black, tarry stools; coughing up or vomiting fresh or dried blood that looks like coffee grounds; severe headache; and weakness. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Drug and Pregnancy Interactions
Major
Prednisone
+ Pregnancy
The following applies to the ingredients: Prednisone
Professional Content
This drug should only be used during pregnancy only if the benefit outweighs the risk to the fetus.
AU TGA pregnancy category: A
US FDA pregnancy category: Not assigned
Risk summary: Available data suggest a small but inconsistent increased risk of orofacial clefts with corticosteroid use during the first trimester. Intrauterine growth restriction and decreased birth weight have also been reported with maternal use of corticosteroids during pregnancy, but the underlying maternal condition may have contributed to these risks.
Comments:
-Women who become pregnant while using this drug should be apprised of the potential fetal risks.
-Observe for signs and symptoms of hypoadrenalism in infants exposed to this drug in utero.
-The short-term use of corticosteroids antepartum for the prevention of respiratory distress syndrome does not seem to pose a risk to the fetus or newborn infant.
Animal studies have revealed evidence of teratogenicity at a maternal dose equivalent to 100 mg in a 60 kg human based on body surface area (BSA); fetolethality and fetotoxicity were observed at a maternal dose equivalent to 290 mg in a 60 kg human based on BSA; constriction of the fetal ductus arteriosus has also been observed. There are no adequate and well controlled studies in pregnant women. However, placental and birth weights have been reduced in humans after long term treatment with corticosteroids. Maternal pulmonary edema with inhibition of uterine contractions and fluid overload has also been reported with corticosteroids. Additionally, adrenal cortex suppression may occur in newborns with long term maternal corticosteroid use.
Menstrual irregularities and altered motility and number of spermatozoa have been reported with clinical use of corticosteroids. Animal studies with corticosteroids have revealed impaired male fertility.
AU TGA pregnancy category A: Drugs which have been taken by a large number of pregnant women and women of childbearing age without any proven increase in the frequency of malformations or other direct or indirect harmful effects on the fetus having been observed.
US FDA pregnancy category Not Assigned: The US FDA has amended the pregnancy labeling rule for prescription drug products to require labeling that includes a summary of risk, a discussion of the data supporting that summary, and relevant information to help health care providers make prescribing decisions and counsel women about the use of drugs during pregnancy. Pregnancy categories A, B, C, D, and X are being phased out.
References
- "Product Information. Rayos (prednisone)." Horizon Therapeutics USA Inc (2016):
- "Product Information. PredniSONE (predniSONE)." Hikma USA (formerly West-Ward Pharmaceutical Corporation) DailyMed (2024):
- "Product Information. Panafcort (prednisone)." Aspen Pharmacare Australia Pty Ltd (2022):
Minor
Vitamin B12
+ Pregnancy
The following applies to the ingredients: Cyanocobalamin (found in Vitamin B12)
Professional Content
This drug should not be used during pregnancy unless the benefit outweighs the risk to the fetus. (AU)
AU TGA pregnancy category: Exempt
US FDA pregnancy category: C
Comments:
-Vitamin B12 needs are increased in pregnancy.
-Megaloblastic anemia of pregnancy is usually due to folic acid deficiency.
-Do not use for megaloblastic anemia of pregnancy due to folic acid deficiency.
References
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
- Cerner Multum, Inc. "Australian Product Information." O 0
- Allen LH "Multiple micronutrients in pregnancy and lactation: an overview." Am J Clin Nutr 81(S) (2005): 1206S-12S
- "Product Information. Cyanocobalamin (cyanocobalamin)." West Ward Pharmaceutical Corporation (2017):
Drug and Breastfeeding Interactions
Minor
Prednisone
+ Breastfeeding
The following applies to the ingredients: Prednisone
Professional Content
This drug should be used only if clearly needed
Excreted into human milk: Yes
Comments:
-If this drug is necessary, the lowest dose should be prescribed; theoretically, if high maternal doses are necessary, the dose the infant receives may be minimized by avoiding breastfeeding for 4 hours following dosing and using prednisolone instead of prednisone.
Amounts of glucocorticoids excreted into breast milk are low with a total infant daily dose calculated to be up to 0.23% of the maternal daily dose. For doses up to 10 mg/day, the amount of drug an infant receives via breast milk is undetectable; however the milk/plasma ratio increases with doses above 10 mg/day (e.g., 25% of the serum concentration is found in breast milk when dose is 80 mg/day). If this drug is necessary, the lowest dose should be prescribed as high doses of corticosteroids for long periods could produce infant growth and development problems and interfere with endogenous corticosteroid production. High doses might occasionally cause temporary loss of milk supply.
References
- "Product Information. Deltasone (prednisone)." Pharmacia and Upjohn PROD (2001):
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
- Cerner Multum, Inc. "Australian Product Information." O 0
- United States National Library of Medicine "Toxnet. Toxicology Data Network. http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT" (2013):
- "Product Information. Rayos (prednisone)." Horizon Therapeutics USA Inc (2016):
- "Product Information. PredniSONE (prednisone)." Watson Pharmaceuticals (2016):
Minor
Vitamin B12
+ Breastfeeding
The following applies to the ingredients: Cyanocobalamin (found in Vitamin B12)
Professional Content
Use is not recommended; benefit to mother should outweigh risk to the infant. (AU)
Excreted into human milk: Yes
Comments:
-Vitamin B12 needs are increased in lactation.
-Deficiency has been seen in breast fed children of vegetarian mothers, even with no symptoms of maternal deficiency.
-Four micrograms daily of B12 are recommended during lactation.
References
- Ehrlich A, Koch T, Amin B, et al. "Development and reliability testing of a standardized questionnaire to assess psoriasis phenotype." J Am Acad Dermatol 54 (2006): 987.e1-14
- Cerner Multum, Inc. "Australian Product Information." O 0
- "Product Information. Nascobal (cyanocobalamin)." Par Pharmaceutical Inc (2017):
Therapeutic Duplication Warnings
No warnings were found for your selected drugs.Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Switch to: Professional Interactions
| Drug Interaction Classification | |
|---|---|
These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication. |
|
| Major | Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. |
| Moderate | Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. |
| Minor | Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. |
| Unknown | No interaction information available. |
Disclaimer: This content should not be considered complete and should not be used in place of a call or visit to a healthcare professional. Use of this content is subject to our terms of use & medical disclaimer.